ChinaBio News

ChinaBio will appear in the Feb. issue of Nature Biotechnology.

Click Here to Download

Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
In the News

ChinaBio will appear in the Feb. issue of Nature Biotechnology.

Click Here to Download

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Simcere to Develop Cancer Drug from OSI Pharma in China

publication date: Oct 20, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group (先声药业) has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase I trial. Terms of the agreement were not disclosed. More details...

Stock Symbols: (NYSE: SCR) (NSDQ: OSIP)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

SEED Finalists Coaching Day
March 2, 2010
Shanghai, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
 
Partner Events

March 8–10, 2010
Barcelona, Spain

World CRO Summit 2010
March 11-12, 2010
Shanghai, China

BIO-Europe 2010
Munich, Germany
November 15–17, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners